Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) was the target of unusually large options trading activity on Monday. Stock investors purchased 832 call options on the stock. This is an increase of 605% compared to the typical volume of 118 call options.

Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $8.50 on Thursday. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $10.50. The firm has a market cap of $466.42, a P/E ratio of -13.71 and a beta of 174.68.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The firm had revenue of $0.80 million during the quarter. analysts anticipate that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.

In related news, Director David P. Hochman acquired 10,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was purchased at an average cost of $7.08 per share, with a total value of $70,800.00. Following the completion of the acquisition, the director now directly owns 459,500 shares of the company’s stock, valued at $3,253,260. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David P. Hochman acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were bought at an average cost of $6.55 per share, with a total value of $32,750.00. Following the completion of the acquisition, the director now directly owns 459,500 shares of the company’s stock, valued at $3,009,725. The disclosure for this purchase can be found here. Insiders acquired 25,336 shares of company stock valued at $175,632 over the last ninety days. Corporate insiders own 11.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in CRBP. State Board of Administration of Florida Retirement System bought a new stake in Corbus Pharmaceuticals during the third quarter valued at approximately $108,000. Yellowstone Partners LLC bought a new stake in Corbus Pharmaceuticals during the third quarter valued at approximately $110,000. Voya Investment Management LLC bought a new stake in Corbus Pharmaceuticals during the second quarter valued at approximately $125,000. Capital Fund Management S.A. bought a new stake in Corbus Pharmaceuticals during the second quarter valued at approximately $130,000. Finally, Credit Suisse AG bought a new stake in Corbus Pharmaceuticals during the first quarter valued at approximately $157,000. Institutional investors own 27.84% of the company’s stock.

Several research firms have recently weighed in on CRBP. Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the company an “overweight” rating in a report on Thursday, December 14th. BidaskClub cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals in a report on Saturday, December 23rd. Finally, ValuEngine cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $25.00.

ILLEGAL ACTIVITY NOTICE: This article was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/04/stock-traders-purchase-high-volume-of-corbus-pharmaceuticals-call-options-crbp.html.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.